US · Healthcare · Biotechnology
EPS came in at -0.09 against a street estimate of -0.10 — a beat of 10.0%.
Analysts rate ATAI Life Sciences BV a strong buy (7 buy, 0 hold, 0 sell out of 7) with an average price target of $8.10.
| Fund | Stake |
|---|---|
| Deep Track Capital, LP | 3.89% |
| Vanguard Capital Management, LLC | 3.17% |
| UBS Group AG | 2.00% |
| BlackRock Inc | 1.84% |
| Adage Capital Partners Gp LLC | 1.52% |
| Susquehanna International Group, LLP | 1.43% |
| Morgan Stanley - Brokerage Accounts | 1.04% |
| Candriam Luxembourg S.C.A. | 0.83% |
| Document | Date |
|---|---|
| Acquisition completed · Q3 2026 ATAIBECKLEY INC. - FORM 8-K SUMMARY September 11, 2026 --- HEADLINE NUMBERS • Merger completed: AtaiBeckley Inc. acquired by Eli Lilly and Company | 2026-09-11 |
| Shareholder vote results · Q3 2026 ATAIBECKLEY INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company held special stockholder meeting on September 8, 2026 • 370,864,669 shares of common | 2026-09-08 |
| Company announcement · Q3 2026 ATAIBECKLEY INC. - FORM 8-K SUMMARY HEADLINE NUMBERS • Company: AtaiBeckley Inc. (Nasdaq: ATAI), Delaware corporation • Filing Date: August 31, 2026 | 2026-08-31 |
| Quarterly report · Q2 2026 ATAIBECKLEY INC. — 10-Q SUMMARY FOR RETAIL INVESTORS HEADLINE NUMBERS • Cash Position: $168.8 million in cash and cash equivalents as of June 30, 20 | 2026-08-11 |
| Material agreement · Q3 2026 ATAIBECKLEY INC. FORM 8-K SUMMARY HEADLINE NUMBERS • Acquisition price: $6.75 per share in cash (Closing Amount) • Contingent value rights (CVRs): U | 2026-07-16 |
| Shareholder vote results · Q2 2026 ATAIBECKLEY INC. (ATAI) – FORM 8-K SUMMARY HEADLINE NUMBERS • Outstanding shares as of April 9, 2026: 366,916,896 common shares • Quorum attendance: | 2026-06-08 |
| Quarterly report · Q1 2026 ATAIBECKLEY INC. - FORM 10-Q SUMMARY (Q1 2026) HEADLINE NUMBERS • Cash position: $43.1 million in cash and cash equivalents as of March 31, 2026, do | 2026-05-12 |
| Proxy statement · Q2 2026 ATAIBECKLEY INC. — 2026 PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Elect three Class I directors—Sabrina Martucci Johnson | 2026-04-22 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $6.75 / share ex-date Sep 9, 2026 | 2026-09-09 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for ATAI Life Sciences BV — free to start.
Google PlayApp StoreData updated 2026-09-18.